Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
What Alivus files
- Investor Meet54
- Others29
- Updates18
- Important9
- Board Meeting8
- PPTs7
Alivus Life Sciences Limited has announced its participation in an in-person investor and analyst meet at the Kotak Healthcare Forum in Mumbai. Company representatives will engage in group and one-on-one meetings to interact with institutional participants.
Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.
Alivus Life Sciences has announced in-person group and one-on-one meetings with various mutual funds and institutions in Mumbai to discuss company operations.
Alivus Life Sciences will hold one-on-one investor meetings in Mumbai with Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital. The schedule and mode are subject to change.
Alivus Life Sciences will hold one-on-one meetings with Mirae Asset (US) on August 28, Emkay Global and SIMPL on September 1, and Lyptus Capital on September 2. These interactions will be virtual or in-person in Mumbai.